971 related articles for article (PubMed ID: 27343248)
1. Molecular Pharmacology of δ-Opioid Receptors.
Gendron L; Cahill CM; von Zastrow M; Schiller PW; Pineyro G
Pharmacol Rev; 2016 Jul; 68(3):631-700. PubMed ID: 27343248
[TBL] [Abstract][Full Text] [Related]
2. Aiming at Ideal Therapeutics-MOPr/DOPr or MOPr-DOPr Heteromertargeting Ligand.
Fujita W
Curr Top Med Chem; 2020; 20(31):2843-2851. PubMed ID: 32324516
[TBL] [Abstract][Full Text] [Related]
3. Alleviating pain with delta opioid receptor agonists: evidence from experimental models.
Berthiaume S; Abdallah K; Blais V; Gendron L
J Neural Transm (Vienna); 2020 Apr; 127(4):661-672. PubMed ID: 32189076
[TBL] [Abstract][Full Text] [Related]
4. [Functional selectivity of opioid receptors ligands].
Audet N; Archer-Lahlou E; Richard-Lalonde M; Piñeyro-Filpo G
Med Sci (Paris); 2010; 26(8-9):734-9. PubMed ID: 20819711
[TBL] [Abstract][Full Text] [Related]
5. Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain.
Jimenez-Vargas NN; Gong J; Wisdom MJ; Jensen DD; Latorre R; Hegron A; Teng S; DiCello JJ; Rajasekhar P; Veldhuis NA; Carbone SE; Yu Y; Lopez-Lopez C; Jaramillo-Polanco J; Canals M; Reed DE; Lomax AE; Schmidt BL; Leong KW; Vanner SJ; Halls ML; Bunnett NW; Poole DP
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15281-15292. PubMed ID: 32546520
[TBL] [Abstract][Full Text] [Related]
6. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
Ananthan S
AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
[TBL] [Abstract][Full Text] [Related]
7. Non-peptidic δ opioid receptor agonists and antagonists (2000 - 2012).
Fujii H; Takahashi T; Nagase H
Expert Opin Ther Pat; 2013 Sep; 23(9):1181-208. PubMed ID: 23705966
[TBL] [Abstract][Full Text] [Related]
8. Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands.
Charfi I; Audet N; Bagheri Tudashki H; Pineyro G
Br J Pharmacol; 2015 Jan; 172(2):435-48. PubMed ID: 24665881
[TBL] [Abstract][Full Text] [Related]
9. LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief.
Pasquinucci L; Parenti C; Georgoussi Z; Reina L; Tomarchio E; Turnaturi R
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299443
[TBL] [Abstract][Full Text] [Related]
10. The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy.
Quock RM; Burkey TH; Varga E; Hosohata Y; Hosohata K; Cowell SM; Slate CA; Ehlert FJ; Roeske WR; Yamamura HI
Pharmacol Rev; 1999 Sep; 51(3):503-32. PubMed ID: 10471416
[No Abstract] [Full Text] [Related]
11. Ligand-specific recycling profiles determine distinct potential for chronic analgesic tolerance of delta-opioid receptor (DOPr) agonists.
Bagheri Tudashki H; Haddad Y; Charfi I; Couture R; Pineyro G
J Cell Mol Med; 2020 May; 24(10):5718-5730. PubMed ID: 32279433
[TBL] [Abstract][Full Text] [Related]
12. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
13. Recent advances on the δ opioid receptor: from trafficking to function.
Gendron L; Mittal N; Beaudry H; Walwyn W
Br J Pharmacol; 2015 Jan; 172(2):403-19. PubMed ID: 24665909
[TBL] [Abstract][Full Text] [Related]
14. Delta opioid receptor-mediated analgesia is not altered in preprotachykinin A knockout mice.
Dubois D; Gendron L
Eur J Neurosci; 2010 Dec; 32(11):1921-9. PubMed ID: 21044181
[TBL] [Abstract][Full Text] [Related]
15. Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.
Beaudry H; Gendron L; Morón JA
Eur J Neurosci; 2015 Apr; 41(7):901--7. PubMed ID: 25639561
[TBL] [Abstract][Full Text] [Related]
16. The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neuropathic pain in mice.
Hervera A; Negrete R; Leánez S; Martín-Campos J; Pol O
J Pharmacol Exp Ther; 2010 Sep; 334(3):887-96. PubMed ID: 20498253
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
[TBL] [Abstract][Full Text] [Related]
18. Conformationally sampled pharmacophore for peptidic delta opioid ligands.
Bernard D; Coop A; MacKerell AD
J Med Chem; 2005 Dec; 48(24):7773-80. PubMed ID: 16302816
[TBL] [Abstract][Full Text] [Related]
19. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
